{
    "clinical_study": {
        "@rank": "62127", 
        "arm_group": [
            {
                "arm_group_label": "UDCA+placebo group", 
                "arm_group_type": "Experimental", 
                "description": "15-30mg/kg/d UDCA for 2 months + placebo for 2 months"
            }, 
            {
                "arm_group_label": "placebo+UDCA", 
                "arm_group_type": "Experimental", 
                "description": "placebo for 2 months+15-30mg/kg/d UDCA for 2 months"
            }, 
            {
                "arm_group_label": "control group", 
                "arm_group_type": "No Intervention", 
                "description": "placebo for 2 months + placebo for 2 months"
            }
        ], 
        "brief_summary": {
            "textblock": "The efficacy of UDCA in treating the parenteral nutrition-associated cholestasis(PNAC) has\n      been identified by  some studies in children without short bowel syndrome(SBS).Most of the\n      adults who suffering PNAC have SBS. it limits the potential function of UDCA  because of the\n      lack of SBS patients and malabsorption of UDCA.Therefore, we design this clinical trial in\n      our center of SBS to approach the preventative and therapeutical effect of UDCA to PNAC in\n      adults with short bowel syndrome."
        }, 
        "brief_title": "The Preventative and Therapeutical Effect of Ursodeoxycholic Acid(UDCA) to Short Bowel Syndrome Patients", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Short Bowel Syndrome", 
        "condition_browse": {
            "mesh_term": "Short Bowel Syndrome"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with short bowel syndrome supported by total parenteral nutrition.\n\n          -  Patients have intestine more than 50cm.\n\n          -  Requirements of informed consent and assent of participant, parent or legal guardian\n             as applicable\n\n          -  Consciousness and ability to cooperate.\n\n        Exclusion Criteria:\n\n          -  Patients have obstruction of biliary tract, infection, autoimmune disease, cancer\n\n          -  Patients have intestine less than 50cm\n\n          -  A clinically significant laboratory abnormality or a history of significant cardiac,\n             pulmonary, hepatic, or renal disease\n\n          -  Female with positive pregnancy\n\n          -  Allergy to ursodeoxycholic acid"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01974336", 
            "org_study_id": "UDCA-PNAC-SBS"
        }, 
        "intervention": {
            "arm_group_label": [
                "UDCA+placebo group", 
                "placebo+UDCA"
            ], 
            "intervention_name": "ursodeoxycholic acid", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Ursodeoxycholic Acid"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "October 26, 2013", 
        "location": {
            "contact": {
                "email": "wenchengkong@gmail.com", 
                "last_name": "Wencheng Kong, MD", 
                "phone": "15850722032"
            }, 
            "contact_backup": {
                "email": "jian.wang@foxmail.com", 
                "last_name": "jian wang"
            }, 
            "facility": {
                "address": {
                    "city": "Nanjing", 
                    "country": "China", 
                    "state": "Jiangsu", 
                    "zip": "200002"
                }, 
                "name": "Jinling Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Wencheng Kong, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "jian wang, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Danhua Yao, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "3", 
        "official_title": "The Preventative and Therapeutical Effect of Ursodeoxycholic Acid(UDCA) to Parenteral Nutrition-associated Cholestasis in Short Bowel Syndrome", 
        "overall_contact": {
            "email": "wenchengkong@gmail.com", 
            "last_name": "Wengcheng Kong, MD", 
            "phone": "15850722032"
        }, 
        "overall_contact_backup": {
            "email": "liys@medmail.com.cn", 
            "last_name": "Yousheng Li", 
            "phone": "8602580860137"
        }, 
        "overall_official": {
            "affiliation": "Nanjing University", 
            "last_name": "Wencheng Kong, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "detect the biochemical indicator of patients' liver function(Serum bilirubin, GGT Valley, lactate dehydrogenase, alanine aminotransferase, aspartate aminotransferase) during oral UDCA or placebo", 
            "measure": "The biochemical indicator of patients' liver function during oral UDCA or placebo", 
            "safety_issue": "Yes", 
            "time_frame": "2 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01974336"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Jinling Hospital, China", 
            "investigator_full_name": "Kong Wencheng", 
            "investigator_title": "Senior Resident", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "we test the composition of serum bile acid at the beginning,2 months,4 months(the end) of the trial", 
                "measure": "the changs of composition of serum bile acid  after oral UDCA or placebo", 
                "safety_issue": "Yes", 
                "time_frame": "2 months"
            }, 
            {
                "description": "we test the level of FGF19 in the serum at the beginning,2 months,4months(the end) of the trail.", 
                "measure": "The changs of the level of fibroblast growth factor 19(FGF19) in the serum", 
                "safety_issue": "Yes", 
                "time_frame": "4 months"
            }
        ], 
        "source": "Jinling Hospital, China", 
        "sponsors": {
            "collaborator": {
                "agency": "National Natural Science Foundation of China", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Jinling Hospital, China", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}